• Citer

Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy.

par Awada, Ahmad ;Piccart-Gebhart, Martine ;Jones, Suzanne F;Peck, Ronald A;Gil, Thierry ;Lebwohl, David;Wu, Chi-Yuan;Burris, Howard A
Référence Cancer chemotherapy and pharmacology, 63, 3, page (417-425)
Publication Publié, 2009-02

Article révisé par les pairs

• Détails
• Contenu

Titre:	Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy.
Auteur:	Awada, Ahmad; Piccart-Gebhart, Martine; Jones, Suzanne F; Peck, Ronald A; Gil, Thierry; Lebwohl, David; Wu, Chi-Yuan; Burris, Howard A
Informations sur la publication:	Cancer chemotherapy and pharmacology, 63, 3, page (417-425)
Statut de publication:	Publié, 2009-02
Sujet CREF:	Sciences bio-médicales et agricoles
Mots-clés:	Dose-finding
	Ixabepilone
	Solid tumors
	Weekly schedule
MeSH keywords:	Aged
	Antineoplastic Agents -- administration & dosage
	Antineoplastic Agents -- adverse effects
	Antineoplastic Agents -- therapeutic use
	Cohort Studies
	Epothilones -- administration & dosage
	Epothilones -- adverse effects
	Epothilones -- pharmacokinetics
	Epothilones -- therapeutic use
	Female
	Humans
	Male
	Maximum Tolerated Dose
	Middle Aged
	Neoplasms -- drug therapy
Note générale:	Clinical Trial, Phase I
	Journal Article
	Research Support, Non-U.S. Gov't
Langue:	Anglais
Identificateurs:	urn:issn:0344-5704
	info:doi/10.1007/s00280-008-0751-5
	info:scp/58249142470
	info:pmid/18446338